Patent Portfolio – 3DT Holdings

Research & Development

Projects Driving Medical Progress

From concept to clinic — our portfolio spans cardiovascular devices, metabolic therapeutics, and diagnostic platforms at varying stages of development.

Research & Development

Active Programs

Patent Portfolio

3DT owns a portfolio of over 200 issued and pending patents that cover inventions in the areas of electrical conductance-enabled therapeutic devices, retroperfusion-enabling devices, devices enabling pericardial access, smart clamps, magnetic occlusion and endograft/endoprosthesis devices, A-Fib/stroke prevention, valve removal / annulus remodeling, and bariatric devices.

Stage

Preclinical → Phase II

Indication

Coronary Artery Disease

Pathway

FDA 510(k)

All Projects

Conductance Balloon Coronary Post-Dilatation Catheter

Stent malapposition leads to less optimal outcomes (restenosis and thrombosis) in coronary stenting.

Stabilization Device for Trans-septal Access

Transseptal (TS) procedures for accessing the left side of the heart are an important and rapidly growing space for diagnostics and therapy delivery.

Mild Hypothermia Catheter for Reperfusion Injury

ST segment elevation myocardial infarction (STEMI) is the most severe form of acute coronary syndrome (ACS) that affects nearly 500,000 Americans each year and places a heavy clinical and financial burden on the healthcare system.

Valvuloplasty

Aortic stenosis (AS) affects approximately 1.5 million Americans and places a large financial burden on the U.S. healthcare system.

Patent Portfolio

3DT owns a portfolio of over 200 issued and pending patents that cover inventions in the areas of electrical conductance-enabled therapeutic devices, retroperfusion-enabling devices,

NIH Sponsored Research

3DT is a recipient of National Institutes of Health (NIH) research grants. 3DT has policies and procedures in place to support these grants and ensure compliance with federal regulations including